Takeda has unveiled its second microbiome pact in a week to continue its gastrointestinal deal spree.

OncoMed shares tanked after its Celgene-partnered lead asset flunked a phase 2 pancreatic cancer trial and Bayer walked away from two drugs.

Johnson & Johnson has deferred making a decision about whether to drop or commit to Geron’s imetelstat.

Johnson & Johnson has become the latest Big Pharma to turn to PeptiDream for help discovering and optimizing peptide therapeutics.

With two failed trials, Aviragen is looking at strategic alternatives to breathe new life into its business, and says it will cut its headcount by 25%.

Two years out from the U.K.'s scheduled EU exit date, the life science sector is increasingly confident about its post-Brexit prospects.

Bristol-Myers Squibb will tap into the immuno-oncology expertise of the Parker Institute and Cancer Research Institute (CRI) in a bid to accelerate clinical…

Shares in Cerulean Pharma nosedived yesterday after the company agreed to sell off its anticancer assets at a bargain basement price and merge with Daré…

Pierre Fabre has teamed with an immuno-oncology spinout from the French Alternative Energies and Atomic Energy Commission to run drug discovery projects.

Astellas Pharma has struck a drug discovery deal worth up to $100 million per target with X-Chem.

Partnering